Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
Primary Purpose
Non-small Cell Lung Cancer Stage I
Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Post-SABR Biopsy
Sponsored by

About this trial
This is an interventional diagnostic trial for Non-small Cell Lung Cancer Stage I
Eligibility Criteria
Inclusion Criteria:
- Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
- Age > 18 year
- Confirmed non-small cell lung cancer after initial biopsies
- Patient with accessible tumor for biopsy
- Patient is to have sufficient initial core biopsy samples for tissue analyses
- Stage I lung cancer
- Adequate normal organ and marrow function
- Patient with tumor amenable to SABR treatment as determined by a radiation oncologist
- Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- Post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
Exclusion Criteria:
- Primary tumors not amenable to serial core biopsies.
- Prior thoracic radiation in the region that will be treated by SABR.
- Patient may not be receiving any other concurrent investigational agents or chemotherapy.
- Patient may not be receiving or received immunotherapy.
- Patients may not be on or use steroids within 14 days before radiation, and from the duration of radiation to the time of the post-SABR biopsies and blood samples.
- Female patients who are pregnant from screening to completion of SABR
Sites / Locations
- Bayview Medical Center
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Stage I NSCLC with SABR Therapy
Arm Description
Participants receive stereotactic ablative radiotherapy (SABR) and pre-SABR biopsy as part of standard of care and then receive a post-SABR biopsy after receiving SABR.
Outcomes
Primary Outcome Measures
Induced T-cell receptor (TCR) profile changes in tumor after stereotactic ablative radiotherapy (SABR) as determined by number of times increase in amount of identified TCR CDR3 regions.
Secondary Outcome Measures
Full Information
NCT ID
NCT03603002
First Posted
July 18, 2018
Last Updated
May 30, 2023
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1. Study Identification
Unique Protocol Identification Number
NCT03603002
Brief Title
Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
Official Title
Studying the Pathologic and Immunologic Response After Ablative Radiation in Stage I Non-Small Cell Lung Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 16, 2018 (Actual)
Primary Completion Date
December 31, 2022 (Actual)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a pilot study to compare pre- and post-SABR core biopsies of stage I NSCLC tumors to identify SABR-induced immune-mediated tumor recognition based on a significant and specific expansion of T-cell clones using a novel T-cell receptor (TCR) sequencing assay. This will be coupled with (1) novel genomic analysis of candidate tumor antigens that may be released from the pre-SABR tumor and (2) functional validation assays to screen post-treatment peripheral blood T-cells for reactivity to these released candidate tumor antigens. In addition, cell-based analysis will be used to identify changes in key T-cell infiltrates into the post-SABR tumor.
Detailed Description
Lung cancer is the leading cause of cancer death in the United States. While stereotactic ablative radiotherapy (SABR) is delivered as standard treatment in patients with medically inoperable stage I non-small cell lung cancer (NSCLC), an alarming 30-40% of these patients still develop disease recurrence just outside of the radiation field and deadly distant metastases in their lifetime. Furthermore, since the abscopal response was reported in advanced NSCLC where a systemic cancer response was induced in areas away from the irradiated site when radiation was combined with immunotherapy, multiple clinical trials are currently investigating the role of combining these two modalities. Significantly, how SABR alone increases immunogenicity of a tumor is unknown. There is a critical need to elucidate the mechanism by which SABR alone incites the immune system to better develop future rational combinations of immunotherapy with SABR.
SABR induced cell death will ultimately activate downstream cytotoxic T-cells and cause T-cell influx into the tumor to enhance immunogenic tumor cell kill. This is accomplished with SABR-induced tumor antigen-both mutation-associated neoantigen and tumor-associated antigen- release, priming of downstream cytotoxic T-cells, leading to specific T-cell clonal expansion, and resultant influx of these activated cytotoxic T-cells into the tumor and blood to enhance immune-mediated tumor cell kill.
Herein the investigator proposes a pilot study to compare pre- and post-SABR core biopsies of stage I NSCLC tumors to identify SABR-induced immune-mediated tumor recognition based on a significant and specific expansion of T-cell clones using a novel T-cell receptor (TCR) sequencing assay. This will be coupled with (1) novel genomic analysis of candidate tumor antigens that may be released from the pre-SABR tumor and (2) functional validation assays to screen post-treatment peripheral blood T-cells for reactivity to these released candidate tumor antigens. In addition, cell-based analysis will be used to identify changes in key T-cell infiltrates into the post-SABR tumor.
The results of this pilot study may have the potential to translate into improved systemic outcomes for patients with NSCLC through future integrated trials of immune checkpoint blockade antibodies that specifically relieve the immunosuppression on the T-cell population found to be activated by SABR. Clarifying SABR-induced immune changes in the tumor and blood will identify pathways that may be exploited to enhance systemic immunity to kill micro-metastatic disease and mitigate relapse in the next generation of clinical trials.
Additional corollary imaging studies using dual-energy (DE) computed tomography (CT), a novel imaging modality that improves the material decomposition ability of CTs, may identify new imaging markers for post-SABR treatment response by comparing DE-CT imaging characteristics with SABR fields and pathologic response.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer Stage I
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Compare pre- and post-SABR core biopsies of stage I NSCLC tumors to identify SABR-induced immune-mediated tumor recognition based on a significant and specific expansion of T-cell clones using a novel T-cell receptor (TCR) sequencing assay.
Masking
None (Open Label)
Allocation
N/A
Enrollment
7 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Stage I NSCLC with SABR Therapy
Arm Type
Experimental
Arm Description
Participants receive stereotactic ablative radiotherapy (SABR) and pre-SABR biopsy as part of standard of care and then receive a post-SABR biopsy after receiving SABR.
Intervention Type
Diagnostic Test
Intervention Name(s)
Post-SABR Biopsy
Intervention Description
Post-SABR Biopsy
Primary Outcome Measure Information:
Title
Induced T-cell receptor (TCR) profile changes in tumor after stereotactic ablative radiotherapy (SABR) as determined by number of times increase in amount of identified TCR CDR3 regions.
Time Frame
Baseline to up to 7 days after SABR treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Written informed consent obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
Age > 18 year
Confirmed non-small cell lung cancer after initial biopsies
Patient with accessible tumor for biopsy
Patient is to have sufficient initial core biopsy samples for tissue analyses
Stage I lung cancer
Adequate normal organ and marrow function
Patient with tumor amenable to SABR treatment as determined by a radiation oncologist
Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
Post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal subjects. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
Exclusion Criteria:
Primary tumors not amenable to serial core biopsies.
Prior thoracic radiation in the region that will be treated by SABR.
Patient may not be receiving any other concurrent investigational agents or chemotherapy.
Patient may not be receiving or received immunotherapy.
Patients may not be on or use steroids within 14 days before radiation, and from the duration of radiation to the time of the post-SABR biopsies and blood samples.
Female patients who are pregnant from screening to completion of SABR
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Khinh Ranh Voong, MD
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Bayview Medical Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21224
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
We'll reach out to this number within 24 hrs